Italy · Delayed Price · Currency is EUR Philogen Company Description
Philogen S.p.A., a biotechnology company, engages in the research and development of drugs for oncology and chronic inflammatory diseases in Italy, Switzerland, the United States, and the European Union.
The company develops Nidlegy which is in Phase III clinical trial for the treatment of advanced melanoma and Phase II clinical trial for the treatment of basal cell carcinoma and cutaneous squamous cell carcinoma; Fibromun which is in Phase III clinical trial for the treatment of soft-tissue sarcoma and Phase II clinical trial for the treatment of glioblastoma; Darleukin which is in Phase II clinical trial for the treatment of non-small cell lung cancer; Dekavil which is in Phase II clinical trial for the treatment of chronic inflammatory disorders; and Dodekin which is in Phase I clinical trial for the treatment of various solid tumors.
It is also involved in the development of small molecule products, including OncoFAP which is in Phase I clinical trial for the treatment of solid tumors; OncoACP3 which is in Phase I clinical trial for the treatment of prostate cancer; and OncoCAIX which is in Phase 1 trial for the treatment of renal cell carcinoma and other hypoxic tumors.
The company was founded in 1996 and is headquartered in Sovicille, Italy.
| Country | Italy |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 214 |
| CEO | Dario Neri |
Contact Details
Address: Via Bellaria, 35 Sovicille, SI 53018 Italy | |
| Phone | 39 057 717816 |
| Website | philogen.com |
Stock Details
| Ticker Symbol | PHIL |
| Exchange | Borsa Italiana |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | IT0005373789 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Prof. Dario Neri Ph.D. | Co-Founder, Chief Executive Officer , MD, CSO, President of the Scientific Advisory Board and Director |
| Dr. Duccio Neri | Co-Founder and Executive Chairman |
| Dr. Giovanni Neri | Co-Founder, MD, Head of IP and Licensing and Executive Director |
| Laura Baldi | Chief Financial Officer |
| Dr. Emanuele Puca | Head of Investor Relations |
| Carolina Pepi | Head of Human Resources |
| Dr. Alfredo Covelli M.D. | Chief Medical Officer |
| Dr. Katia Lorizzo | Deputy CMO and Head of Clinical Operations |